Keyphrases
HF-rTMS
100%
Treatment-resistant Depression
100%
Multicenter Cohort Study
100%
Chronic Treatment
100%
Selective Serotonin Reuptake Inhibitors
100%
Placebo-controlled
18%
Sham
18%
No Significant Difference
9%
Patients Included
9%
Patient Well-being
9%
Tolerability
9%
Monotherapy
9%
Headache
9%
Adverse Events
9%
Open Study
9%
Treatment Options
9%
Multicenter Trial
9%
Double-blind Placebo-controlled Trial
9%
Inhibitor Treatment
9%
Dropout
9%
Motor Threshold
9%
Screening Data
9%
Carry-over Effects
9%
Quality of Alternatives
9%
Comparative Efficacy
9%
Protocol Parameters
9%
Thrice Weekly
9%
Nursing and Health Professions
Long Term Care
100%
Transcranial Magnetic Stimulation
100%
Selective Serotonin Reuptake Inhibitor
100%
Treatment Resistant Depression
100%
Placebo
27%
Drug Therapy
9%
Adverse Event
9%
Quality of Life
9%
Pulse Rate
9%
Headache
9%
Monotherapy
9%
Neuroscience
Transcranial Magnetic Stimulation
100%
Selective Serotonin Reuptake Inhibitor
100%
Treatment-Resistant Depression
100%
Placebo
27%
Headache
9%
Pharmacology, Toxicology and Pharmaceutical Science
Selective Serotonin Reuptake Inhibitor
100%
Treatment Resistant Depression
100%
Placebo
42%
Adverse Event
14%
Tolerability
14%
Monotherapy
14%
Headache
14%